Phaseline

Companies › PureTech

PureTech: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Respiratory; next expected readout Nov 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Deupirfenidone (LYT-100)
Deuterated pirfenidone analogue; antifibrotic agent
–Phase 3Idiopathic Pulmonary Fibrosis (IPF); Idiopathic Pulmonary FibrosisNov 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05321420Deupirfenidone (LYT-100)Phase 2Idiopathic Pulmonary FibrosisRespiratoryOct 2024
NCT07284602Deupirfenidone (LYT-100)Phase 3Idiopathic Pulmonary Fibrosis (IPF)RespiratoryNov 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biotest Areteia Therapeutics Renovion Youssef Yammine Kringle Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.